Cefuroxime (DrugBank: Cefuroxime)
2 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
97 | Ulcerative colitis | 1 |
299 | Cystic fibrosis | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00355602 (ClinicalTrials.gov) | July 2006 | 21/7/2006 | Antibiotics for the Treatment of Ulcerative Colitis | Use of Antibiotics to Eradicate Bacterial Pathogens Colonising the Colonic Mucosa in Ulcerative Colitis Patients | Colitis, Ulcerative | Drug: Cefuroxime;Drug: Ciprofloxacin;Drug: Clarithromycin;Drug: Cotrimoxazole;Drug: Coamoxiclav;Drug: metronidazole;Drug: neomycin;Drug: rifaximin;Drug: Vancomycin;Drug: Doxycycline | University of Dundee | Tenovus Scotland | Completed | 18 Years | 79 Years | Both | 40 | N/A | United Kingdom |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2019-003501-10-SE (EUCTR) | 07/04/2020 | Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study. | Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study. - MBWtodetectPEXinCF | Cystic fibrosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | INN or Proposed INN: AMOXICILLIN INN or Proposed INN: CLAVULANIC ACID INN or Proposed INN: AMOXICILLIN INN or Proposed INN: FLUCLOXACILLIN INN or Proposed INN: DICLOXACILLIN INN or Proposed INN: SULFAMETHOXAZOLE INN or Proposed INN: Trimetoprim Other descriptive name: TRIMETHOPRIM INN or Proposed INN: Clarithromycin Other descriptive name: CLARITHROMYCIN INN or Proposed INN: RIFAMPICIN INN or Proposed INN: DOXYCYCLINE INN or Proposed INN: Fusidic acid Other descriptive name: FUSIDIC ACID INN or Proposed INN: Ciprofloxacin Other descriptive name: CIPROFLOXACIN INN or Proposed INN: Linezolid Other descriptive name: LINEZOLID INN or Proposed INN: CLINDAMYCIN Other descriptive name: CLINDAMYCIN INN or Proposed INN: Cefuroxim Other descriptive name: CEFUROXIME INN or Proposed INN: CEFALEXIN | Västra Götalandsregionen | NULL | NA | Female: yes Male: yes | 100 | Phase 4 | Sweden | |||
2 | EUCTR2019-003501-10-DK (EUCTR) | 22/04/2020 | Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study. | Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study. - MBWtodetectPEXinCF | Cystic fibrosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | INN or Proposed INN: AMOXICILLIN INN or Proposed INN: CLAVULANIC ACID INN or Proposed INN: AMOXICILLIN INN or Proposed INN: FLUCLOXACILLIN INN or Proposed INN: DICLOXACILLIN INN or Proposed INN: SULFAMETHOXAZOLE INN or Proposed INN: Trimetoprim Other descriptive name: TRIMETHOPRIM INN or Proposed INN: Clarithromycin Other descriptive name: CLARITHROMYCIN INN or Proposed INN: RIFAMPICIN INN or Proposed INN: DOXYCYCLINE INN or Proposed INN: Fusidic acid Other descriptive name: FUSIDIC ACID INN or Proposed INN: Ciprofloxacin Other descriptive name: CIPROFLOXACIN INN or Proposed INN: Linezolid Other descriptive name: LINEZOLID INN or Proposed INN: CLINDAMYCIN Other descriptive name: CLINDAMYCIN INN or Proposed INN: Cefuroxim Other descriptive name: CEFUROXIME INN or Proposed INN: CEFALEXIN | Västra Götalandsregionen | NULL | NA | Female: yes Male: yes | 100 | Phase 4 | Denmark;Sweden |